ZS802
/ Sichuan Real & Best Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 21, 2025
The Efficacy and Safety of ZS802 in Chinese Hemophilia A Patients.
(clinicaltrials.gov)
- P=N/A | N=6 | Recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting ➔ Recruiting | Trial completion date: Oct 2024 ➔ Oct 2025 | Trial primary completion date: Oct 2024 ➔ Oct 2025
Enrollment open • Trial completion date • Trial primary completion date • Hematological Disorders • Hemophilia • Hemophilia A • Rare Diseases
1 to 1
Of
1
Go to page
1